ALS Ice Bucket Challenge Progress


We Can't Wait.

We Can't Wait

Every day we get closer to pioneering new therapies that can help people with ALS live longer, better lives. But we need your help to invest in this promising ALS research.

Please consider making a gift today to help us reach our goal of raising $300,000+ for ALS research this year.

It's not a matter of if, it's only a matter of when we find a cure for ALS.


ALS is a complex disease, and we're fighting it on all fronts.

We are on the brink of groundbreaking new therapies as The ALS Association's collaborative approach is leading to significant discoveries by top ALS scientists worldwide.

Just a few years ago, some of these research advanacements would have been inconceivable. Today, people living with ALS here in Oregon and SW Washington are taking part in groundbreaking clinical trials.

Like them, we will never give up hope that, with life-extending treatment options, ALS can become a manageable disease. One day soon, we will all live without fear of ALS winning. 


Research Updates

ALS Genetic Therapies


Antisense therapy effectively "silences" the gene causing ALS. One type of antisense therapy, Tofersen, may slow the progression of ALS in people with a certain type of familial ALS. Tofersen should be available to people living with ALS as early as mid-July 2021.

Cell Therapy


Initial research into cell therapy of regulatory T cells, also known as Tregs, has shown promising results in the race to find new treatments for people living with ALS. Patients who had Tregs extracted, expanded, and then infused back have had slower ALS progression.


HEALEY ALS Platform Trial


This initiative will lead to new ALS treatments at a faster rate. During clinical trials, many treatments will be tested at once. It reduces the cost of research by 30%, decreases trial time by 50%, and increases patient participation by 67%.


Professor Bechman

Dr. Joe Beckman at Oregon State University has led research on copper compound Cu-ATSM. Cu-ATSM only delivers copper to damaged cells, leaving healthy cells unharmed and reducing the damage caused by ALS. This therapy is now being studied at the University of Melbourne in Australia. Our Chapter of The ALS Association has provided over $600,000 in funding for Cu-ATSM research.